Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07783009 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT07783009 · ClinicalTrials.gov record · last posted 2026-08-24

An Expanded Access Program to Provide Divarasib to Participants With Previously Treated KRAS G12c-Positive Advanced or Metastatic Non-Small Cell Lung Cancer

Name: An Expanded Access Program to Provide Divarasib to Participants With Previously Treated KRAS G12c-Positive Advanced or Metastatic Non-Small Cell Lung Cancer — clinical trial record (NCT07783009)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusAvailable

PhaseNot specified

SponsorGenentech, Inc.

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

The purpose of this expanded access program (EAP) is to provide early access to divarasib to participants with KRAS G12C-positive (KRAS G12C+) advanced or metastatic non-small cell lung cancer (NSCLC), prior to divarasib becoming commercially available in the United States.

Trial Details

NCT Number	NCT07783009
Lead Sponsor	Genentech, Inc.
Conditions	Non-Small Cell Lung Cancer
Updated on ClinicalTrials.gov	2026-08-24